KRAS and cancer: However, discovering drugs that could benefit patients with cancer whose tumors harbor KRAS G12D and KRAS G12V mutations remains a significant unmet need, because the prevalence in human cancers of these mutations is higher than that of KRAS G12C mutations (9).